Evidence summary
What the cited records say
FDA's Epitalon briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.↗↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
Cited context
Related records
Dated source history
Updates connected to this profile
Regulatory
FDA committee met on seven peptide-related groups of bulk drug substances↗
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗